8-K: Cadrenal Therapeutics Files Prospectus Supplement for $2.17 Million At-the-Market Offering

Cadrenal Therapeutics announced the filing of a prospectus supplement for an at-the-market offering of up to $2.17 million shares of its common stock.

Summary

• Cadrenal Therapeutics filed a prospectus supplement with the SEC on April 17, 2025, regarding an at-the-market offering program.
• The offering involves up to $2,169,272 shares of the company's common stock.
• H.C. Wainwright & Co., LLC is acting as the sales agent for the offering, pursuant to an existing At the Market Offering Agreement dated March 11, 2024.
• As of April 17, 2025, the company has already sold $7,655,240 of shares under the ATM Agreement.
• The offering is made under a registration statement on Form S-3, initially filed on March 12, 2024, and declared effective on March 20, 2024.
• Wainwright will receive compensation of 3.0% of the gross sales price of all shares sold through the ATM Agreement.
• The company retains the right to suspend solicitation and offers under the ATM Agreement at any time.

Sentiment

Score: 6

Explanation: The announcement is fairly neutral. While the capital raise provides the company with funds, it also dilutes existing shareholders. The terms of the ATM offering seem standard.

Positives

• The at-the-market offering provides Cadrenal Therapeutics with a flexible way to raise capital.
• The company has the option to suspend the offering at any time, giving them control over the process.

Negatives

• The offering will dilute existing shareholders' ownership.
• The company will incur fees of 3.0% of the gross sales price to H.C. Wainwright & Co., LLC.

Risks

• The company may not be able to sell all of the shares offered.
• Market conditions could affect the price at which the shares are sold.
• The offering could negatively impact the company's stock price.

Future Outlook

The company may offer and sell shares of its common stock from time to time through H.C. Wainwright & Co., LLC, subject to the terms and conditions of the ATM Agreement.

Industry Context

At-the-market offerings are a common way for companies, especially smaller ones, to raise capital in a flexible manner. They allow companies to sell shares into the existing trading market over time, which can be less disruptive than a traditional underwritten offering.

Comparison to Industry Standards

• Comparable companies in the biotechnology sector, such as XOMA Corporation and Agenus Inc., have also utilized ATM offerings to raise capital.
• The 3.0% commission to Wainwright is within the typical range for ATM offerings, which generally fall between 1% and 5%.

Stakeholder Impact

• Shareholders will experience dilution of their ownership.
• The company will have additional capital to fund its operations.

Key Dates

Keywords

at-the-market offering, common stock, Cadrenal Therapeutics, H.C. Wainwright, prospectus supplement, capital raise